Craft

Amgen

Stock Price

$310.9

2024-07-05

Market Capitalization

$166 B

2024-07-05

Revenue

$28.2 B

FY, 2023

Amgen Summary

Company Summary

Overview
Amgen (formerly known as Applied Molecular Genetics) is a biotechnology company that discovers, develops, manufactures, and delivers human therapeutics. It focuses on oncology and hematology, cardiovascular disease, inflammation, bone health, nephrology, and neuroscience. The company operates a range of brands, including Aimovig, Aranesp, BLINCYTO, Corlanor, KYPROLIS, EVENITY, NEUPOGEN, etc.
Type
Public
Status
Active
Founded
1980
HQ
Thousand Oaks, CA, US | view all locations
Website
https://www.amgen.com/
Cybersecurity rating
ESG rating
60-79 out of 100|View all ESG data
Sectors

Key People

  • Robert A. Bradway

    Robert A. Bradway, Chairman and Chief Executive Officer

  • Peter Griffith

    Peter Griffith, Executive Vice President and Chief Financial Officer

  • David M. Reese

    David M. Reese, Executive Vice President and Chief Technology Officer

  • James Bradner

    James Bradner, Executive Vice President, Research and Development, and Chief Scientific Officer

Operating MetricsView all

Distribution Centers (Foreign)

3

FY, 2020

Countries

100

FY, 2020

Patents (US)

31
8.8%

FY, 2020

LocationsView all

65 locations detected

  • Thousand Oaks, CA HQ

    United States

    1 Amgen Center Dr

  • Cambridge, MA

    United States

    360 Binney St

  • Louisville, KY

    United States

    12000 Plantside Dr

  • South San Francisco, CA

    United States

    1120 Veterans Blvd

  • Tampa, FL

    United States

    2202 N Westshore Blvd

  • Washington, DC

    United States

    601 13th St NW 12th Floor

and 59 others

Amgen Financials

Summary Financials

Revenue (Q1, 2024)
$7.4B
Gross profit (Q1, 2024)
$4.2B
Net income (Q1, 2024)
($113.0M)
Cash (Q1, 2024)
$9.7B
EBIT (Q1, 2024)
$991.0M
Enterprise value
$221.4B

Footer menu